Open Clinical Trials:
CLINICAL TRIAL 17747
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 19722
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20113
Phase 1/2 FIH Study of Regn5458 (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20130
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20141
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20253
Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20361
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies and In Combination With Daratumumab As A Salvage Regimen for Multiple Myeloma
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20753
An Open-Label Phase I, Multi-Center Study to Determine the Recommended Dose of the Chimeric Antigen Receptor T-cell Treatment CYAD-211 After a Non-Myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients with Relapsed or Refractory Disease (IMMUNICY-1)
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 20781
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 21249
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 18926
The National Myelodysplastic Syndromes (MDS) Study
Disease Site: Leukemia, other, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia
View Trial DetailsCLINICAL TRIAL 20156
Mindfulness in AYA Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pilot Proposal
Disease Site: Multiple Myeloma, Unknown Sites, Leukemia, other
View Trial DetailsCLINICAL TRIAL 20816
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Disease Site: Multiple Myeloma
View Trial DetailsCLINICAL TRIAL 21219
Predicting Progression of Developing Myeloma in a High-Risk Screened Population
Disease Site: Multiple Myeloma
View Trial Details